Neurocrine Biosciences Intends to File Shelf Registration Statement
SAN DIEGO, Nov. 13 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it intends to file a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC), which, when declared effective, will permit Neurocrine Biosciences, from time to time, to offer and sell up to $200 million of common stock, preferred stock and debt securities.
Neurocrine intends to use the net proceeds from subsequent offerings for general corporate purposes, including continued development and clinical trials of our NBI-34060 product candidate addressing insomnia and various other product candidates, research and development expenses, general and administrative expenses, manufacturing expenses, and potential acquisitions of companies and technologies that complement our business.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Neurocrine Biosciences. The offering of Neurocrine Biosciences will be made only by means of a prospectus.
For further information, please contact: Elizabeth Foster or Paul Hawran, both of Neurocrine Biosciences, Inc., +1-858-658-7600.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X45844398
SOURCE Neurocrine Biosciences, Inc.
Web site: http: //www.neurocrine.com
CONTACT: Elizabeth Foster or Paul Hawran, both of Neurocrine Biosciences, Inc., +1-858-658-7600